MCID: CCN002
MIFTS: 48

Cocaine Abuse

Categories: Mental diseases

Aliases & Classifications for Cocaine Abuse

MalaCards integrated aliases for Cocaine Abuse:

Name: Cocaine Abuse 12 55 15 72
Cocaine-Related Disorders 44 72

Classifications:



External Ids:

Disease Ontology 12 DOID:809
ICD9CM 35 305.6 305.60
MeSH 44 D019970
SNOMED-CT 68 78267003
ICD10 33 F14.1
UMLS 72 C0009171 C0236736

Summaries for Cocaine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cocaine despite negative consequences.

MalaCards based summary : Cocaine Abuse, also known as cocaine-related disorders, is related to cocaine dependence and personality disorder. An important gene associated with Cocaine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Neuroscience. The drugs Risperidone and Amantadine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Cocaine Abuse

Diseases related to Cocaine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 334)
# Related Disease Score Top Affiliating Genes
1 cocaine dependence 31.1 SLC6A4 SLC6A3 DRD2 DBH
2 personality disorder 31.0 SLC6A4 SLC6A3 PRL DRD2
3 substance abuse 30.9 SLC6A4 SLC6A3 PRL DRD2 DBH
4 eating disorder 30.8 SLC6A4 SLC6A3 DRD2
5 galactorrhea 30.5 PRL DRD2
6 peripartum cardiomyopathy 30.4 PRL DRD2
7 conduct disorder 30.3 SLC6A4 SLC6A3 DRD2 DBH
8 tic disorder 30.2 SLC6A3 SLC18A2 DRD2
9 substance dependence 30.2 SLC6A4 SLC6A3 DRD2
10 schizoaffective disorder 30.2 SLC6A4 PRL DRD2
11 agoraphobia 30.2 SLC6A4 SLC6A2
12 bipolar disorder 30.1 SLC6A4 SLC6A3 SLC18A2 DRD2
13 antisocial personality disorder 30.0 SLC6A4 SLC6A3 MAOB DRD2
14 panic disorder 29.9 SLC6A4 SLC6A2 HTR3A
15 sexual disorder 29.9 SLC6A4 PRL
16 movement disease 29.7 SNCA SLC6A3 SLC18A2 DRD2
17 migraine with or without aura 1 29.6 SLC6A4 HTR3A DRD2 DBH
18 major depressive disorder 29.6 SLC6A4 SLC6A3 SLC6A2 PRL HTR3A DRD2
19 disease of mental health 29.5 SNCA SLC6A4 SLC6A3 SLC6A2 DRD2
20 post-traumatic stress disorder 29.4 SLC6A4 MAOB DRD2
21 alcohol dependence 29.2 SLC6A4 SLC6A3 MAOB HTR3A DRD2 DBH
22 attention deficit-hyperactivity disorder 28.5 SLC6A4 SLC6A3 SLC6A2 SLC18A2 MAOB DRD2
23 psychotic disorder 28.0 SLC6A4 SLC6A3 SLC18A2 PRL MAOB HTR3A
24 parkinson disease, late-onset 27.9 SNCA SLC6A4 SLC6A3 SLC18A2 MAOB DRD2
25 schizophrenia 27.3 SLC6A4 SLC6A3 SLC6A2 SLC18A2 PRL MAOB
26 vasculitis 10.6
27 schizophreniform disorder 10.5 PRL DRD2
28 prolactin producing pituitary tumor 10.5 PRL DRD2
29 periodic limb movement disorder 10.5 SLC6A4 DRD2
30 rem sleep behavior disorder 10.4 SNCA SLC6A3
31 functioning pituitary adenoma 10.4 PRL DRD2
32 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.4
33 alcohol-induced mental disorder 10.4 SLC6A4 SLC6A3 DRD2
34 alcoholic psychosis 10.4 SLC6A4 SLC6A3 DRD2
35 placental abruption 10.4
36 alexithymia 10.4 SLC6A4 DRD2
37 striatonigral degeneration 10.3 SNCA SLC6A3 DRD2
38 migraine without aura 10.3 SLC6A4 PRL DRD2
39 avoidant personality disorder 10.3
40 hard palate cancer 10.3
41 drug dependence 10.3
42 cocaine intoxication 10.3
43 stuttering 10.3 SLC6A3 DRD2 DBH
44 myocardial infarction 10.3
45 alcohol use disorder 10.3
46 myocarditis 10.3
47 acute myocardial infarction 10.3
48 tobacco addiction 10.3 SLC6A4 SLC6A3 DRD2
49 arteriovenous malformation 10.3
50 visual epilepsy 10.3

Graphical network of the top 20 diseases related to Cocaine Abuse:



Diseases related to Cocaine Abuse

Symptoms & Phenotypes for Cocaine Abuse

GenomeRNAi Phenotypes related to Cocaine Abuse according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR3A SIGMAR1 SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR3A SIGMAR1 SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR3A SIGMAR1 SLC6A4

MGI Mouse Phenotypes related to Cocaine Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 DBH DRD2 HTR3A MAOB PRL SIGMAR1
2 homeostasis/metabolism MP:0005376 10 BCHE DBH DRD2 HTR3A MAOB PRL
3 endocrine/exocrine gland MP:0005379 9.87 DBH DRD2 HTR3A PRL SLC6A3 SLC6A4
4 integument MP:0010771 9.81 DBH DRD2 HTR3A PRL SLC17A8 SLC6A2
5 nervous system MP:0003631 9.7 DBH DRD2 HTR3A MAOB PRL SLC17A8
6 taste/olfaction MP:0005394 9.02 DRD2 GRK3 SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Cocaine Abuse

Drugs for Cocaine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 314)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
2
Amantadine Approved Phase 4 768-94-5 2130
3
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7
Choline Approved, Nutraceutical Phase 4 62-49-7 305
8 calcium channel blockers Phase 4
9 Calcium, Dietary Phase 4
10 Tranquilizing Agents Phase 4
11 Dopamine Antagonists Phase 4
12 Antipsychotic Agents Phase 4
13 Gastrointestinal Agents Phase 4
14 Antiparkinson Agents Phase 4
15 Nootropic Agents Phase 4
16 Sodium Channel Blockers Phase 4
17 Antimanic Agents Phase 4
18 Cytidine Diphosphate Choline Phase 4
19 Quetiapine Fumarate Phase 4 111974-72-2
20 Diuretics, Potassium Sparing Phase 4
21 Antimetabolites Phase 4
22 Hypolipidemic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Lecithin Phase 4
25
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 3 52485-79-7 40400 644073
26
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
27
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
28
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
29
Levodopa Approved Phase 2, Phase 3 59-92-7 6047
30
Naltrexone Approved, Investigational, Vet_approved Phase 2, Phase 3 16590-41-3 5360515
31
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 5195 26757
32
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359
33
Entacapone Approved, Investigational Phase 2, Phase 3 130929-57-6 5281081
34
Naloxone Approved, Vet_approved Phase 2, Phase 3 465-65-6 5284596
35
Biperiden Approved, Investigational Phase 3 514-65-8 2381
36
Nicotine Approved Phase 3 54-11-5 942 89594
37
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245
38
Bupropion Approved Phase 2, Phase 3 34841-39-9, 34911-55-2 444
39
Methadone Approved, Illicit Phase 2, Phase 3 76-99-3 4095
40 Serotonin Receptor Agonists Phase 2, Phase 3
41 Serotonin Uptake Inhibitors Phase 2, Phase 3
42 Serotonin and Noradrenaline Reuptake Inhibitors Phase 3
43 Hormone Antagonists Phase 2, Phase 3
44 Progestins Phase 2, Phase 3
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
46 Parasympatholytics Phase 3
47 Muscarinic Antagonists Phase 3
48 Cytochrome P-450 Enzyme Inducers Phase 3
49 Wakefulness-Promoting Agents Phase 3
50 Cholinergic Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 412)
# Name Status NCT ID Phase Drugs
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4 caffeine;Biperiden;Placebo
2 The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
3 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
4 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
5 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
6 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
7 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
8 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
9 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
10 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
11 A Randomized, Double-blind, Placebo-controlled, Trial of Lamotrigine add-on Therapy in Outpatients With Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence Completed NCT00280293 Phase 4 Lamotrigine;Placebo
12 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction: The Role of Glutamate Completed NCT02626494 Phase 4 N-Acetylcystein;Placebo
13 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
14 Neuroplasticity Following Theta-Burst Stimulation in Cocaine Use Recruiting NCT02927236 Phase 4
15 Brain Imaging: Cocaine Effects & Medication Development Withdrawn NCT00000270 Phase 4 Cocaine
16 Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts Withdrawn NCT02134002 Phase 4 Disulfiram;Placebo
17 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
18 Medication Development for Cocaine Dependence Unknown status NCT00249691 Phase 3 Topiramate + Cognitive Behavioral Therapy;Placebo + Cognitive Behavioral Therapy
19 Effect of Nefazodone on Relapse in Females With Cocaine Abuse Completed NCT00000293 Phase 3 Nefazodone
20 Dose Response Trial of Pergolide for Cocaine Dependence Completed NCT00000248 Phase 3 Pergolide
21 A Double-blind, Placebo-controlled Trial of Citicoline add-on Therapy in Patients With a History of Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3 Citicoline;Placebo
22 A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence Completed NCT00553319 Phase 2, Phase 3 Placebo;Adderall-XR;Adderall-XR
23 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts Completed NCT00000216 Phase 3 Buprenorphine
24 Combining Behavioral Treatment With Agonist Maintenance Completed NCT00000311 Phase 3 Buprenorphine;methadone
25 Double-Blind, Placebo-Controlled Trial of Selegiline Transdermal System for the Treatment of Cocaine Dependence Completed NCT00032929 Phase 3 Selegiline
26 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3 Caffeine;Biperiden;Placebo
27 Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients Completed NCT01134198 Phase 2, Phase 3 Mifepristone;placebo
28 Treatment of Adult ADHD in Methadone Patients Completed NCT00061087 Phase 2, Phase 3 Methylphenidate;Bupropion
29 Cocaine Use Reduction With Buprenorphine (CURB) Completed NCT01402492 Phase 2, Phase 3 Buprenorphine + Naltrexone;Placebo + Naltrexone
30 Cocaine/Crack Dependence: A Study of the Possible Reduction of Compulsion Under the Use of Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
31 Vigabatrin for Treatment of Cocaine Dependence: A Phase II Study Completed NCT01281202 Phase 2, Phase 3 Vigabatrin;Matching Placebo
32 Smoking-Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking-Cessation and Stimulant Treatment on Stimulant-Dependence Outcomes Completed NCT01077024 Phase 3
33 Project 1: Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3 Escitalopram;Placebo
34 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00167232 Phase 3 Naltrexone
35 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3 Oral micronized progesterone;Placebo
36 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence Completed NCT01811940 Phase 2, Phase 3 Adderall-ER;Topiramate
37 Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients Completed NCT02255357 Phase 2, Phase 3 Placebo;Intranasal Oxytocin
38 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3 levodopa carbidopa and entacapone (LCE);Placebo
39 Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study Completed NCT00701532 Phase 3 Modafinil and PET (brain imaging);placebo
40 Naltrexone and Psychosocial Treatments for the Treatment of Cocaine Dependence Complicated by Alcohol Dependence Completed NCT00218660 Phase 3 Naltrexone;Placebo
41 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3 medication management
42 Bupropion-Enhanced CM for Cocaine Dependence Recruiting NCT02111798 Phase 2, Phase 3 Bupropion XL;placebo
43 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Active, not recruiting NCT02774954 Phase 3
44 Treating Cocaine Abuse: A Behavioral Approach Unknown status NCT01822327 Phase 2
45 Effect of Magnetic Stimulation Repetitive Transcranial on Impulsivity in Cocaine Dependence. Unknown status NCT01397266 Phase 2
46 A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Unknown status NCT00737256 Phase 2 Aripiprazole;Perphenazine
47 Efeitos da Estimulacao Magnetica Transcrania de Repeticao ( EMTr) no Tratamento da Dependencia ao Uso de Cocaina Unknown status NCT01259362 Phase 2
48 Randomised Placebo-Controlled Trial of Modafinil for Cocaine Dependence Unknown status NCT00123383 Phase 2 Modafinil
49 Effect of Repetitive Transcranial Magnetic Stimulation on Symptoms of Attention Deficit Hyperactivity Disorder and Cognitive Function In Cocaine Addicts Unknown status NCT01593982 Phase 2
50 Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving Unknown status NCT01929343 Phase 2 lidocaine following cue-induced craving;lidocaine following neutral stimulus;saline

Search NIH Clinical Center for Cocaine Abuse

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Maprotiline
Maprotiline Hydrochloride

Cochrane evidence based reviews: cocaine-related disorders

Genetic Tests for Cocaine Abuse

Anatomical Context for Cocaine Abuse

MalaCards organs/tissues related to Cocaine Abuse:

41
Brain, Testes, Cortex, Prefrontal Cortex, Heart, Placenta, Pituitary

Publications for Cocaine Abuse

Articles related to Cocaine Abuse:

(show top 50) (show all 2254)
# Title Authors PMID Year
1
Disulfiram: an old therapeutic with new applications. 9 38
20201810 2010
2
Model of human butyrylcholinesterase tetramer by homology modeling and dynamics simulation. 9 38
19402731 2009
3
Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines. 9 38
19253970 2009
4
Expression of transcripts for myelin related genes in postmortem brain from cocaine abusers. 9 38
18357522 2009
5
Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. 9 38
20230764 2009
6
Nonhuman primate neuroimaging and cocaine medication development. 9 38
19086766 2008
7
Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. 9 38
18579413 2008
8
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. 9 38
17897630 2008
9
Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies? 9 38
17291372 2007
10
Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in the human striatum. 9 38
16110277 2005
11
PET imaging of dopamine D2 receptors in monkey models of cocaine abuse: genetic predisposition versus environmental modulation. 9 38
16055768 2005
12
Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. 9 38
15879005 2005
13
Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. 9 38
15740791 2005
14
Conformational analysis of methylphenidate: comparison of molecular orbital and molecular mechanics methods. 9 38
15865064 2004
15
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. 9 38
12801223 2003
16
Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. 9 38
12565970 2003
17
The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates. 9 38
11408518 2001
18
Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. 9 38
10881032 2000
19
Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. 9 38
10869397 2000
20
3-Aryl-2-carbomethoxybicyclo[3.2.1]oct-2-enes inhibit WIN 35,428 binding potently and selectively at the dopamine transporter. 9 38
10732975 2000
21
Dopamine transporter mRNA in autopsy studies of chronic cocaine users. 9 38
10581411 1999
22
Ibogaine and cocaine abuse: pharmacological interactions at dopamine and serotonin receptors. 9 38
8995326 1997
23
[The dopamine transporter: characterization and physiopathologic implications]. 9 38
8674469 1995
24
Clonidine, an α2 adrenergic receptor agonist, disrupts reconsolidation of a cocaine-paired environmental memory. 38
31386639 2019
25
Miniaturized analytical platform for cocaine detection in oral fluids by MicroNIR/Chemometrics. 38
31171220 2019
26
Nasal Septum Defects Detected on Postmortem Computed Tomography. 38
30985333 2019
27
A Case of Isolated Left Ventricular Non-Compaction Cardiomyopathy in a HIV Patient Presenting With Acute Heart Failure. 38
31413781 2019
28
Cocaine-induced ANCA-associated renal disease: a case-based review. 38
31401698 2019
29
Better executive function is independently associated with full HIV suppression during combination therapy. 38
31436611 2019
30
Pneumomediastinum as a complication of cocaine abuse. 38
31308113 2019
31
Sensorimotor Gating in Cocaine-Related Disorder with Comorbid Schizophrenia or Antisocial Personality Disorder. 38
31287382 2019
32
The SERT Met172 Mouse: An Engineered Model To Elucidate the Contributions of Serotonin Signaling to Cocaine Action. 38
30817127 2019
33
Transient left ventricular acute failure after Cocaine Use. 38
31333135 2019
34
Microvascular Reconstruction of the Nose with the Radial Forearm Flap: A 17-Year Experience in 47 Patients. 38
31246830 2019
35
The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report. 38
31182138 2019
36
Gambling Disorder in Male Violent Offenders in the Prison System: Psychiatric and Substance-Related Comorbidity. 38
29971589 2019
37
Development of a long-acting Fc-fused cocaine hydrolase with improved yield of protein expression. 38
30986387 2019
38
Chronic cocaine administration upregulates FKBP5 in the extended amygdala of male and female rats. 38
31029877 2019
39
Cocaine-induced changes in the expression of NMDA receptor subunits. 38
31204625 2019
40
Cocaine-induced Thrombosis: Review of Predisposing Factors, Potential Mechanisms, and Clinical Consequences with a Striking Case Report. 38
31355062 2019
41
Euglycemic diabetic ketoacidosis. 38
30910328 2019
42
Valsalva retinopathy associated with intranasal cocaine abuse: A case report. 38
30207173 2019
43
A high-quality homology model for the human dopamine transporter validated for drug design purposes. 38
30721576 2019
44
Modulation of striatal dopamine dynamics by cocaine self-administration and amphetamine treatment in female rats. 38
31111573 2019
45
Comments to: Valsalva retinopathy associated with intranasal cocaine abuse: A case report. 38
30945570 2019
46
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse? 38
31276119 2019
47
Short-term withdrawal from repeated exposure to cocaine during adolescence modulates dynorphin mRNA levels and BDNF signaling in the rat nucleus accumbens. 38
30818133 2019
48
Ruboxistaurin Reduces Cocaine-Stimulated Increases in Extracellular Dopamine by Modifying Dopamine-Autoreceptor Activity. 38
30384585 2019
49
Iron-deficiency Anemia Causes an Ischemic Stroke in a Young Man. 38
31106101 2019
50
D1 receptor hypersensitivity in mice with low striatal D2 receptors facilitates select cocaine behaviors. 38
30504927 2019

Variations for Cocaine Abuse

Expression for Cocaine Abuse

Search GEO for disease gene expression data for Cocaine Abuse.

Pathways for Cocaine Abuse

Pathways related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 SLC6A3 SLC18A2 SLC17A8 MAOB GRK3 DRD2
2 12.29 SNCA SIGMAR1 GRK3 DBH
3 11.83 SLC6A4 SLC6A3 SLC6A2
4
Show member pathways
11.77 SLC6A4 SLC18A2 SLC17A8
5
Show member pathways
11.69 SLC6A3 SLC18A2 MAOB DRD2
6 11.62 SLC6A4 SLC18A2 MAOB HTR3A
7 11.09 SNCA SLC6A3 MAOB
8 10.99 SLC6A3 SLC18A2
9 10.99 SLC6A4 SLC18A2 HTR3A
10
Show member pathways
10.75 SLC6A4 SLC6A3 BCHE
11
Show member pathways
10.56 SLC6A4 SLC6A3 SLC6A2 DBH
12 10.49 SLC6A2 SLC18A2 DBH

GO Terms for Cocaine Abuse

Cellular components related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SIGMAR1 HTR3A
2 cytoplasmic vesicle GO:0031410 9.83 SLC18A2 SLC17A8 SIGMAR1 DRD2 DBH
3 neuronal cell body GO:0043025 9.8 SNCA SLC6A3 SLC17A8 HTR3A
4 axon GO:0030424 9.78 SNCA SLC6A3 HTR3A DRD2
5 neuron projection GO:0043005 9.72 SLC6A4 SLC6A3 SLC6A2 SLC17A8 HTR3A
6 axon terminus GO:0043679 9.58 SNCA SLC17A8 DRD2
7 synaptic vesicle membrane GO:0030672 9.56 SNCA SLC18A2 SLC17A8 DRD2
8 nuclear outer membrane GO:0005640 9.51 SNCA SIGMAR1
9 dopaminergic synapse GO:0098691 9.33 SLC6A3 SLC18A2 DRD2
10 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 HTR3A DRD2
11 integral component of postsynaptic membrane GO:0099055 8.92 SLC6A4 SLC6A3 HTR3A DRD2
12 membrane GO:0016020 10.23 SNCA SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8
13 integral component of membrane GO:0016021 10.22 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8 SIGMAR1

Biological processes related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.96 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8
2 chemical synaptic transmission GO:0007268 9.83 SNCA SLC6A2 SLC18A2 HTR3A DBH
3 response to toxic substance GO:0009636 9.76 SLC6A4 SLC18A2 MAOB DRD2
4 excitatory postsynaptic potential GO:0060079 9.72 SNCA HTR3A DRD2
5 locomotory behavior GO:0007626 9.71 SLC6A3 SLC18A2 DRD2 DBH
6 positive regulation of multicellular organism growth GO:0040018 9.65 SLC6A3 DRD2
7 associative learning GO:0008306 9.65 DRD2 DBH
8 response to amphetamine GO:0001975 9.65 SLC18A2 DRD2 DBH
9 response to lipopolysaccharide GO:0032496 9.64 SNCA MAOB
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.64 SNCA DRD2
11 response to pain GO:0048265 9.63 SLC6A2 DBH
12 behavioral response to cocaine GO:0048148 9.63 SNCA DRD2
13 synaptic transmission, dopaminergic GO:0001963 9.62 SNCA DRD2
14 response to iron ion GO:0010039 9.62 SLC6A3 DRD2
15 response to cocaine GO:0042220 9.62 SNCA SLC6A3 HTR3A DRD2
16 prepulse inhibition GO:0060134 9.61 SLC6A3 DRD2
17 dopamine metabolic process GO:0042417 9.61 SNCA DRD2
18 neurotransmitter biosynthetic process GO:0042136 9.6 SLC6A4 SLC6A3
19 dopamine biosynthetic process GO:0042416 9.59 SNCA SLC6A3
20 response to nutrient GO:0007584 9.58 SLC6A4 BCHE
21 behavioral response to ethanol GO:0048149 9.58 DRD2 DBH
22 adenohypophysis development GO:0021984 9.57 SLC6A3 DRD2
23 response to ethanol GO:0045471 9.56 SLC6A3 MAOB HTR3A DRD2
24 neurotransmitter transport GO:0006836 9.55 SLC6A4 SLC6A3 SLC6A2 SLC18A2 SLC17A8
25 dopamine transport GO:0015872 9.54 SLC6A3 SLC18A2
26 dopamine catabolic process GO:0042420 9.54 SLC6A3 MAOB DBH
27 neurotransmitter loading into synaptic vesicle GO:0098700 9.52 SLC18A2 SLC17A8
28 dopamine uptake involved in synaptic transmission GO:0051583 9.51 SNCA SLC6A2
29 serotonin uptake GO:0051610 9.49 SLC6A4 SLC18A2
30 monoamine transport GO:0015844 9.26 SLC6A4 SLC6A3 SLC6A2 SLC18A2
31 response to drug GO:0042493 9.17 SNCA SLC6A4 SLC6A3 SLC6A2 MAOB DRD2

Molecular functions related to Cocaine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.54 SLC6A3 SIGMAR1 DRD2
2 alpha-tubulin binding GO:0043014 9.46 SNCA SLC6A2
3 symporter activity GO:0015293 9.46 SLC6A4 SLC6A3 SLC6A2 SLC17A8
4 dopamine binding GO:0035240 9.43 SLC6A3 DRD2
5 serotonin binding GO:0051378 9.4 SLC6A4 HTR3A
6 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A3 SLC6A2
7 serotonin:sodium symporter activity GO:0005335 9.26 SLC6A4 SLC18A2
8 neurotransmitter:sodium symporter activity GO:0005328 9.13 SLC6A4 SLC6A3 SLC6A2
9 monoamine transmembrane transporter activity GO:0008504 8.92 SLC6A4 SLC6A3 SLC6A2 SLC18A2

Sources for Cocaine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....